secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001000694-25-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax Q2 revenue $239M; net income $107M; $175M Sanofi milestone from FDA BLA approval
--------------------------------------------------------------------------------

- Total revenue of $239M, down 42% YoY, includes $175M milestone from Nuvaxovid BLA approval.
- Net income of $107M vs $162M YoY; cash $628M; $175M milestone receipt expected Q3 2025.
- Updated FY2025 adjusted total revenue guidance to $1,000-1,050M (prior $975-1,025M).
- Combined R&D/SG&A expense guidance raised to $495-545M; includes $20M postmarketing study cost.
- Phase 3 data for COVID-flu combo and standalone flu candidates showed robust immune responses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000100069425000031/0001000694-25-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000100069425000031/nvax-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001000694-25-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer